Cell and gene therapy solutions
-
23
Active FDA approved therapies
-
$25B
Anticipated category spend by 2026
-
284
therapies in the pipeline in Phase 1-3 of development
We anticipate 35 novel therapies in the market by 2026. The treatment of rare genetic disorders continues to grow with a target on disorders such as sickle cell, hemophilia, spinal muscular atrophy and several oncology disease states.
Challenging factors
Navigating the complex landscape
- Access: Qualified treatment centers and limited hospital capacity challenge implementation in health systems.
- Cost: The high cost of gene therapy necessitates discussion on long-term affordability and patient assistance programs.
- Reimbursement: Health systems must work closely with their finance and payer management teams to create single-case agreements.
- Operations: Lacking clear guidelines, institutions must individually assess and develop policies for the safe handling of therapies.
$0.00 million
Gene therapies cost as much as $4.25M
Is your P&T committee poised to handle high-cost and clinically complex medications?
Novel and complex advanced therapies, such as cell and gene therapies, present lifesaving opportunities for patients who have few alternatives for care. Hospitals and health systems are adopting new frameworks, including high-cost and cell and gene therapy committees to manage challenges associated with these new therapies. In a recent Vizient study, organizations share how they are structuring their committees to be successful.
Access the executive summary and readiness checklistConnect with our experts
For more information about our cell and gene therapy solutions, contact us.
Speak with our team of experts to learn more
Let’s discuss your challenges
Tell us a little more about how we can help you. Here's what we're going to do with the details you share:
- Identify the person or resource best suited to help you with your challenge.
- Contact you to address it directly.